Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells

Journal of Infectious Diseases

Volumn 201, Issue 8, 2010, Pages 1132-1140

  Szeto, Gregory L ^a   Brice, Angelas ^a   Yang, Hung Chih ^b   Barber, Sheila A ^a   Siliciano, Robert F ^a   Clements, Janice E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; MINOCYCLINE; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; ATTENUATION; CD4+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, VIRAL; CELLS, CULTURED; CYTOKINES; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV; HIV INFECTIONS; HUMANS; LYMPHOCYTE ACTIVATION; MINOCYCLINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIREMIA; VIRUS LATENCY;

EID: 77950258687     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/651277     Document Type: Article

References (30)

1. d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral ther-apy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Pa-tients. AIDS 2000;14: 499-507.
2. Salama NN, Endsley A, Ho RJ. Recent developments in drug targets and delivery of anti-HIV drugs. Infect Disord Drug Targets 2006;6: 107-119.
3. Shehu-Xhilaga M, Tachedjian G, Crowe SM, Kedzierska K. Antiret-roviral compounds: mechanisms underlying failure of HAART to erad-icate HIV-1. Curr Med Chem 2005;12: 1705-1719.
4. McGee B, Smith N, Aweeka E HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV Clin Trials 2006;7: 142-153.
5. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and min-ocycline. Clin Pharmacokinet 1988;15: 355-366.
6. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther 2005;27: 1329-1342.
7. Zink MC, Uhrlaub J, DeWitt J, et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 2005;293: 2003-2011.
8. Kloppenburg M, Verweij CL, Miltenburg AM, et al. The influence of tetracyclines on T cell activation. Clin Exp Immunol 1995;102: 635-641.
9. Kloppenburg M, Brinkman BM, de Rooij-Dijk HH, et al. The tetra-cycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrob Agents Chemother 1996; 40: 934-940.
10. Copeland KF. Modulation of HIV-1 transcription by cytokines and chemokines. Mini Rev Med Chem 2005;5: 1093-1101.
11. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. HIV-1 rep-lication is controlled at the level of T cell activation and proviral in-tegration. Embo J 1990;9: 1551-1560.
12. McDougal JS, Mawle A, Cort SP, et al. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen. J Immunol 1985;135: 3151-3162.
13. Monie D, Simmons RP, Nettles RE, et al. A novel assay allows geno-typing of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients. J Virol 2005;79: 5185-5202.
14. Yang HC, Xing S, Shan L, et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009;119(11): 3473-3486.
15. Zhang H, Zhou Y, Alcock C, et al. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol 2004; 78: 1718-1729.
16. Tong-Starksen SE, Luciw PA, Peterlin BM. Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. Proc Natl Acad Sci USA 1987;84: 6845-6849.
17. Kinoshita S, Su L, Amano M, Timmerman LA, Kaneshima H, Nolan GP. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity 1997;6: 235-244.
18. Cebrian M, Yague E, Rincon M, Lopez-Botet M, de Landazuri MO, Sanchez-Madrid F. Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lympho-cytes. J Exp Med 1988;168: 1621-1637.
19. Alarcón GS. Tetracyclines for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs 2000;9: 1491-1498.
20. Li Y, Mak G, Franza BR Jr. In vitro study of functional involvement of Sp1, NF-kappa B/Rel, and AP1 in phorbol 12-myristate 13-acetate-mediated HIV-1 long terminal repeat activation. J Biol Chem 1994; 269: 30616-30619.
21. Neckers LM, Cossman J. Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2. Proc Natl Acad Sci USA 1983;80: 3494-3498.
22. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci USA 1989;86: 5974-5978.
23. Derdeyn CA, Silvestri G. Viral and host factors in the pathogenesis of HIV infection. Curr Opin Immunol 2005;17: 366-373.
24. Veazey R, Ling B, Pandrea I, McClure H, Lackner A, Marx P. Decreased CCR5 expression on CD4+ T cells of SIV-infected sooty mangabeys. AIDS Res Hum Retroviruses 2003;19: 227-233.
25. Giuliani F, Hader W, Yong VW. Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction. J Leukoc Biol 2005;78: 135-143.
26. Chougnet C, Freitag C, Schito M, Thomas EK, Sher A, Shearer GM. In vivo CD40-CD154 (CD40 ligand) interaction induces integrated HIV expression by APC in an HIV-1-transgenic mouse model. J Im-munol 2001;166: 3210-3217.
27. Sakellari D, Goodson JM, Kolokotronis A, Konstantinidis A. Concentration of 3 tetracyclines in plasma, gingival crevice fluid and saliva. J Clin Periodontal 2000;27: 53-60.
28. Zhang Y, Metz LM, Yong VW, et al. Pilot study of minocycline in re-lapsing-remitting multiple sclerosis. Can J Neurol Sci 2008;35: 185-191.
29. Daoud A, Gloria CJ, Taningco G, et al. Minocycline treatment results in reduced oral steroid requirements in adult asthma. Allergy Asthma Proc 2008;29: 286-294.
30. O'Dell JR, Blakely KW, Mallek JA, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of mino-cycline and hydroxychloroquine. Arthritis Rheum 2001;44: 2235-2241.